Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6411602 | 0.83 | HTR1A (0.52) | ADRB1LMNAALDH1A1SMN1; SMN2AKR1C3 | |
| SCHEMBL4291189 | 0.78 | ADRB1 (0.72) | ADRB1LMNAMCOLN3HTR7ALDH1A1 | |
| SCHEMBL14983590 | 0.78 | ADRB1 (0.56) | ADRB1LMNAMCOLN3HTR7ALDH1A1 | |
| SCHEMBL6031006 | 0.77 | MAPT (0.48) | ADRB1HTR7ALDH1A1SMN1; SMN2 | |
| SCHEMBL6806256 | 0.77 | ADRB1 (0.47) | ADRB1HTR7ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL6031040 | 0.74 | MAPT (0.52) | ADRB1LMNAHTR7ALDH1A1SMN1; SMN2 | |
| SCHEMBL28587090 | 0.73 | ADRB1 (0.60) | ADRB1LMNAMCOLN3HTR7ALDH1A1 | |
| SCHEMBL6736376 | 0.73 | ADRB1 (0.60) | ADRB1LMNAMCOLN3HTR7ALDH1A1 | |
| SCHEMBL11211339 | 0.73 | ATM (0.53) | ADRB1LMNAMCOLN3ALDH1A1AR | |
| SCHEMBL8690323 | 0.73 | ALDH1A1 (0.63) | ADRB1LMNAALDH1A1ARHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101887-B2 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | NEUROGEN CORPORATION (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050239799-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype | NEUROGEN CORPORATION (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239799-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype | DRD2, DRD4, HTR2C | ADRB1 113/4885LMNA 3652/4885MCOLN3 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.